Plain-English translation of NCT06883539 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a new medication called LXP1788 Injection for patients with advanced solid tumors that haven't responded to standard therapies. Researchers want to find the right dose of this medication, understand how it works in your body, and see if it can help shrink tumors. This is a first-in-human study, meaning LXP1788 is being tested in patients for the first time.
Many patients with advanced solid cancers run out of treatment options when standard therapies stop working. This trial exists to explore whether this new medication could offer hope to patients in that situation and to determine whether it is safe enough to test further.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would receive the medication as an intravenous injection once per week in 28-day treatment cycles. You would need to visit the clinic regularly for injections, blood tests, and imaging scans to monitor how you're responding and check for side effects. The study involves about 24 patients total, and researchers will gradually test higher doses to find the safest and most effective dose level.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
Taiwan